Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 602 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event... July 20, 2022 Washington Farmers Harvest Crops For Neighbor With Stage Four Cancer August 5, 2019 How to Cope With and Discuss an Uncertain Cancer Prognosis: An... September 7, 2023 What You Should Know About Receiving Online Medical Test Results and... September 6, 2022 Load more HOT NEWS Breast Cancer May Spread by Recruiting Nearby Sensory Nerves Can we grow the treatments of tomorrow? – That Cancer Conversation Therapy Rottweiler, known as Dogtor Loki, Is Delivering ‘Hero Healing Kits’... Cancer research in 2020: A spotlight on Manchester
